How do you prioritize and time post–liver transplant MASLD surveillance (biopsy vs MRI-based fat quantification vs VCTE/CAP) in recipients at high metabolic risk when recipient factors appear to drive early recurrence risk?

Patients transplanted for Mash have 80-100% recurrence of steatosis (without aggressive weight management), so starting at 1 year and on a 2-3 basis depending on results. This can be VCTE or MRE (what you have access to). Once steatohepatitis is confirmed, depending on stage, it may be q1-2 years. B...